Neoantigen Screening and Discovery Service

Online Inquiry

In the rapidly evolving field of cancer immunotherapy, neoantigens play a pivotal role in the development of personalized treatments. These tumor-specific antigens, which arise from mutations in the DNA of cancer cells, are unique to each individual's tumor. Neoantigen-based therapies have shown great promise in harnessing the body's immune system to selectively target and destroy cancer cells while sparing healthy tissue. Our Neoantigen Screening and Discovery Service offers comprehensive solutions to identify, validate, and prioritize neoantigens for the development of personalized cancer immunotherapies, including cancer vaccines, TIL therapies, and adoptive T-cell therapies.

What Are Neoantigens

Fig.1 Neoantigen. Fig.1 Neoantigen in T cells activation.¹

Neoantigens are peptides that are presented on the surface of tumor cells in association with major histocompatibility complex (MHC) molecules. These peptides are the result of somatic mutations in the DNA of cancer cells and are absent from normal, healthy cells. Because neoantigens are tumor-specific, they represent ideal targets for immunotherapy. The identification of neoantigens that are both immunogenic and tumor-specific is critical to developing targeted treatments that can trigger an effective immune response against cancer.

Neoantigen Screening and Discovery Service at Creative Biolabs

Our Neoantigen Screening and Discovery Service leverages state-of-the-art technologies and expert bioinformatics to identify the most promising neoantigens from a patient's tumor.

Process of Our Service

Fig.2 Process. (Creative Biolabs Original)

The first process begins with obtaining high-quality tumor and normal tissue samples. We then perform whole exome sequencing (WES) or RNA sequencing (RNA-Seq) of the tumor and matched normal tissue to identify genetic mutations specific to the tumor. These mutations are key to identifying potential neoantigens.
Using advanced bioinformatics tools, we analyze the sequencing data to identify mutations that may result in neoantigen formation. The data is then processed to predict which of these mutations are likely to bind to MHC molecules and be presented on the surface of tumor cells.
After identifying potential neoantigen candidates, we utilize cutting-edge algorithms to predict their immunogenicity—i.e., their ability to stimulate a T-cell response. These predictions are based on factors like peptide-MHC binding affinity and the potential for recognition by T-cells. We further validate these neoantigens in vitro using T-cell activation assays to confirm that the neoantigens elicit a robust immune response.
Not all neoantigens are equally effective at inducing immune responses. Our service includes the prioritization of neoantigens based on their immunogenic potential, tumor specificity, and relevance to therapeutic strategies. We help our clients identify the most promising neoantigens for cancer vaccines, TIL therapies, and other immunotherapy approaches.
For preclinical studies, we offer the development of custom neoantigen panels tailored to the specific needs of your research. These panels can be used to track the tumor-specific immune responses or to test the effectiveness of TILs, CAR-T cells, or other immune cell therapies.

Applications of Neoantigen Discovery

Cancer Vaccines

Personalized cancer vaccines that encourage the immune system to identify and target tumor cells can be created using neoantigens. These vaccines are designed to provoke a specific immune response against the identified neoantigens, improving treatment outcomes.

TIL Therapy

By identifying neoantigens that activate TILs, we help to enhance the expansion of tumor-specific TILs, which can then be re-infused into the body to target and destroy cancer cells.

Adoptive T-cell Therapy (ACT)

In ACT, neoantigen-targeted T-cells are expanded ex vivo and infused back into the body. Our neoantigen discovery process helps identify the most effective targets for creating and expanding tumor-specific T-cells for use in ACT.

Combination Therapies

To boost immune responses and get past tumor immune evasion mechanisms, neoantigen-targeted medicines can be used in conjunction with existing immunotherapies, such as checkpoint inhibitors.

Why Choose Us

Fig.3 Applications. (Creative Biolabs Original)

Get Started with Our Neoantigen Screening and Discovery Service

Our Neoantigen Screening and Discovery Service provides the tools and expertise to unlock the full potential of personalized cancer immunotherapies. Whether you are developing a new cancer vaccine, optimizing TIL therapy, or exploring adoptive T-cell treatments, we are here to support your research with high-quality neoantigen identification and validation.

Contact us today to learn more about how our service can help you create targeted, personalized cancer therapies that make a real difference in patient outcomes.

Reference

Nemunaitis, John et al. "Clonal Neoantigen: Emerging "Mechanism-based" Biomarker of Immunotherapy Response." Cancers vol. 15,23 5616. 28 Nov. Distributed under Open Access license CC BY 4.0, without modification.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.